Aimmune Therapeutics
Brisbane
About Aimmune Therapeutics
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 501 – 1,000
- Estimated revenue: $10K – $50K
- Total funding: $540.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2020)
- Ticker: nasdaq:AIMT
- Website: aimmune.com
- Phone: +1 650 614 5220
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aimmune-therapeutics-11706 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.